News

GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society Congress 2025: London, UK Wednesday, September 17, 2025, 11:00 Hrs [IST] GSK ...
EMA committee issues positive opinion on granting ODD to SOM Biotech’s SOM3355 for treatment of Huntington’s disease: Barcelona, Spain Wednesday, September 17, 2025, 10:00 Hrs ...
UK MHRA grants marketing authorization to vorasidenib to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation ...
AiMeD requests additional tax reforms to help industry address persisting challenges: Our Bureau, New Delhi Wednesday, September 17, 2025, 08:00 Hrs [IST] The Association of India ...
World Pharmacists Day celebrations to be held in Surat on Sept 25: Peethaambaran Kunnathoor, Chennai Wednesday, September 17, 2025, 08:00 Hrs [IST] The Gujarat state board of the ...
Cocrystals of approved APIs should go through approval process for new drugs: CDSCO: Gireesh Babu, New Delhi Wednesday, September 17, 2025, 08:00 Hrs [IST] The Central Drugs Stand ...
NABL and the University of Ladakh partner to enhance testing laboratory capabilities and research: Shardul Nautiyal, Mumbai Wednesday, September 17, 2025, 08:00 Hrs [IST] The Nati ...
The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of nine new drugs, including three anti-inflammation fixed dose combinations (FDCs) and six antidiabetic combinations ...
Mycenax Biotech and Spera Pharma collaborate to streamline ADC drug substance and drug product manufacturing services: Taiwan Tuesday, September 16, 2025, 16:00 Hrs [IST] Mycenax ...
Japan’s MHLW approves Novocure’s Optune Lua to treat unresectable advanced/recurrent non-small cell lung cancer: Baar, Switzerland Tuesday, September 16, 2025, 17:00 Hrs [IST] ...
Avanos Medical acquires Nexus Medical to strengthen nutrition and medication delivery in critical care: Alpharetta, Georgia Tuesday, September 16, 2025, 14:00 Hrs [IST] Avanos Med ...
Viridian Therapeutics completes patient enrollment in REVEAL-1 & REVEAL-2 phase 3 trials of VRDN-003 to treat active and chronic TED: Waltham, Massachusetts Tuesday, September 16, ...